Registered entities
Cytomx Therapeutics, Inc.
Reg. No. 1501989United States
Cytomx Therapeutics, Inc
Reg. No. 27-3521219United States
CYTOMX THERAPEUTICS INC.
Reg. No. 273521219United States
Innovation
93 patent families (40 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 22,442 times.
| Year | Filings |
|---|---|
| 2015 | 14 |
| 2016 | 21 |
| 2017 | 21 |
| 2018 | 23 |
| 2019 | 29 |
| 2020 | 38 |
| 2021 | 32 |
| 2022 | 30 |
| 2023 | 34 |
| 2024 | 43 |
| 2025 | 34 |
| 2026 | 16 |
Social engagement
Social engagement: 12.9K social following, 8 posts in the last 12 months — above the industry median.
Investor mix
17 investors on record; lead investors include Canaan, Fidelity Investments, Third Rock Ventures, Pfizer Venture Investments.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 11 | 65% |
| Angel & family office | 1 | 6% |
| Bank & private debt | 1 | 6% |
| Other / undisclosed | 4 | 24% |
Hiring activity
Hires occasionally
1 role tracked across 1 of the last 12 months
10 Jun 2026 · Director / Senior Director, Corporate Strategy & New Product Planning · South San Francisco
Based on job postings tracked across public sources.
Recent activity
18 Jun 2026
Event
BIO2026
3 Jun 2026
Partnership
Regeneron
29 May 2026
Event
ASCO2026